Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · IEX Real-Time Price · USD
45.16
-1.21 (-2.61%)
At close: May 17, 2024, 4:00 PM
46.19
+1.03 (2.28%)
After-hours: May 17, 2024, 7:09 PM EDT
Legend Biotech Employees
Legend Biotech had 1,826 employees on December 31, 2023. The number of employees increased by 436 or 31.37% compared to the previous year.
Employees
1,826
Change (1Y)
436
Growth (1Y)
31.37%
Revenue / Employee
$187,732
Profits / Employee
-$255,173
Market Cap
8.24B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1,826 | 436 | 31.37% |
| Dec 31, 2022 | 1,390 | 319 | 29.79% |
| Dec 31, 2021 | 1,071 | 189 | 21.43% |
| Dec 31, 2020 | 882 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Encompass Health | 37,761 |
| Chemed | 15,087 |
| Elanco Animal Health | 9,800 |
| Bio-Rad Laboratories | 8,030 |
| Bio-Rad Laboratories | 8,030 |
| Globus Medical | 5,000 |
| Penumbra | 4,200 |
| Cerevel Therapeutics Holdings | 334 |
LEGN News
- 5 days ago - Legend Biotech Reports First Quarter 2024 Results and Recent Highlights - Business Wire
- 26 days ago - CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma - Business Wire
- 5 weeks ago - Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results - Business Wire
- 6 weeks ago - Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma - Business Wire
- 2 months ago - Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report - Business Wire
- 2 months ago - CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma - Business Wire
- 2 months ago - Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights - Business Wire
- 3 months ago - Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy - Business Wire